Hematologic Malignancy
Conditions
Brief summary
During the past decades, the wider application of easily available haploidentical donor hematopoietic cell transplant (haplo-HCT) has been made possible through the T cell-replete (TCR) regimens including T cell regulation with anti-thymocyte globulin (ATG)/granulocyte colony-stimulating factor (GCSF) and post-transplant cyclophosphamide (PTCy). To achieve decreased non-relapse mortality (NRM) and improved long-term outcomes in haploidentical transplant, the joint use of ATG and PTCy might effectively reduce graft versus host disease (GVHD) and mortality associated with severe forms of GVHD. Recently, investigators established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse.
Interventions
DRUGCyclophosphamid
A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
DRUGATG
A total of 10mg/kg ATG was administered.
Sponsors
Peking University People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with acute leukemia and/or myelodysplastic syndrome undergoing their first allogeneic hematopoietic stem cell transplantation; 2. Male or female , aged 12-55 years; 3. Haploidentical donor transplantation; 4. ECOG score ≤3; The basic organ function tests met the following standards; 1\) Cardiac ejection index \>55% 2) Creatinine ≤1.5 times the highest normal value (ULN)
Exclusion criteria
1. Severe brain, heart, kidney or liver dysfunction; 2. Refractory malignant state; 3. Patients with other malignant tumors requiring treatment; 4. Clinically uncontrolled severe active infection; 5. The expected survival time was less than 3 months. 6. A history of severe anaphylaxis. 7. Pregnant or lactating women; 8. Any condition considered by the investigators to be unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of acute graft versus host disease. | 100 days post HSCT. | The incidence of acute graft versus host disease. The severity of acute GVHD was evaluated according to standard international criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of chronic GvHD | 1 year post HSCT. | The incidence of chronic GvHD. |
| The incidence of non-relapse mortality | 1 year post HSCT. | The incidence of non-relapse mortality |
| The incidence of infection | 1 year post HSCT. | The incidence of infection |
| The incidence of relapse | 1 year post HSCT. | The incidence of relapse |
| Engraftment | 30 days post HSCT. | Myeloid engraftment was defined as the first of three consecutive days with an ANC X0.5≥10\^9/L. |
| Disease free survival | 1 year post HSCT. | Disease free survival |
| GvHD relapse free survival | 1 year post HSCT. | GvHD relapse free survival |
| Immune reconstitution | 1 year post HSCT. | Immune reconstitution was evaluated at 1, 2, 3, 6, 9 and 12 months by analysis of peripheral blood MNCs detecting CD3, CD4, CD19 and immunoglobulin (Ig) A, G and M levels. |
| Overall survival | 1 year post HSCT. | Overall survival |
Countries
China
Outcome results
None listed